GAVI in talks with China's Sinopharm, other vaccine makers for COVAX doses

FILE PHOTO: A nurse prepares to administer the AstraZeneca/Oxford vaccine under the COVAX scheme against the coronavirus disease (COVID-19) at the Eka Kotebe General Hospital in Addis Ababa, Ethiopia March 13, 2021. REUTERS/Tiksa Negeri/File Photo

GENEVA (Reuters) – The Gavi Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China’s state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a Gavi spokeswoman told Reuters on Monday in response to a query.

Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing’s push for a bigger role in inoculating the world.

Source: Read Full Article

Previous post Largest study to date confirms non-steroidal anti-inflammatory medications do not result in worse COVID-19 outcomes
Next post Preclinical study finds sex differences in neurological response to SARS-CoV-2 infection